Results 31 to 40 of about 6,623 (164)

Patient with homozygous familial hypercholesterolemia: difficult to treat. Case report

, 2020
Homozygous familial hypercholesterolemia is a severe genetic disorder characterized by extremely high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C), as well as by rapid atherosclerosis progression in various vascular ...
Andrey V. Susekov, Irina V. Leontieva, Balakhonova T.V., Vladislav M. Soloviev, Irina M. Miklashevich, Yuliia S. Isaeva   +5 more
core   +1 more source

Baseline characteristics and response to evinacumab in females and males with homozygous familial hypercholesterolemia in the ELIPSE OLE study. [PDF]

Am J Prev Cardiol
Aim: Evinacumab is an ANGPTL-3 inhibitor developed for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare condition characterized by extremely elevated LDL-cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular ...
Brisson D, Wiegman A, Waldron A, Kainth P, Raal FJ, Gaudet D.   +5 more
europepmc   +2 more sources

Treatment of Homozygous Familial Hypercholesterolemia. [PDF]

JACC Adv
Homozygous familial hypercholesterolemia is a rare, life-threatening, genetic disorder characterized by severe hypercholesterolemia, xanthomata, and accelerated atherosclerosis.
Cegla J, Walji S, Barton L, Neuwirth C, Thompson GR.   +4 more
europepmc   +2 more sources

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Atherosclerosis Plus, 2021
Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels.
Maria Giovanna Lupo, Diletta Arcidiacono, Alice Zaramella, Fabio Fimiani, Paolo Calabrò, Angelo Baldassare Cefalù, Maurizio Averna, Laura D'Erasmo, Marcello Arca, Sara De Martin, Alberto Zambon, Nicola Ferri   +11 more
doaj   +1 more source

Case Report: Beating the assumed prognosis: homozygous familial hypercholesterolemia with unexpected long survival. [PDF]

Front Cardiovasc Med
BackgroundFamilial hypercholesterolemia (FH) is a common autosomal codominant genetic disorder, with heterozygous FH (HeFH) affecting approximately 1 in 310 individuals.
Zlatohlávek L, Becherová Beňová J, Foglarová T, Dudková T, Hubáček JA.   +4 more
europepmc   +2 more sources

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Information on the real‐world use of proprotein convertase subtilisin kexin 9 inhibitors (PCKS9is) in familial hypercholesterolemia are limited.
Marcello Arca, Simone Celant, Pier Paolo Olimpieri, Antonietta Colatrella, Luca Tomassini, Laura D'Erasmo, Maurizio Averna, Alberto Zambon, Alberico Luigi Catapano, Pierluigi Russo   +9 more
doaj   +1 more source

Familial hypercholesterolemia: A review

Annals of Pediatric Cardiology, 2014
Familial hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism resulting in elevated serum low-density lipoprotein (LDL) cholesterol levels leading to increased risk for premature cardiovascular diseases (CVDs).
Mithun J Varghese
doaj   +1 more source

LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives

, 2010
Coronary artery diseases (CAD) inflict a heavy economical and social burden on most populations and contribute significantly to their morbidity and mortality rates.
Charles Coutelle, Harbottle, R, Anna L David, Themis, M, Al-Allaf, FA, Waddington, SN, David, A, Faisal A Al-Allaf, Michael Themis, Coutelle, C, Simon N Waddington, Richard Harbottle   +11 more
core   +1 more source

Treatment of Homozygous Familial Hypercholesterolemia With EvinacumabNovel Teaching Points

CJC Open, 2022
Patients with homozygous familial hypercholesterolemia (HoFH) have extremely elevated levels of low-density lipoprotein cholesterol (LDL-C), with premature atherosclerosis and aortic valve disease.
Natasha Jeraj, BSc, Shih-Han S. Huang, MD, Brooke A. Kennedy, BSc, Robert A. Hegele, MD   +3 more
doaj   +1 more source

Apolipoprotein B metabolism in homozygous familial hypercholesterolemia.

Journal of Lipid Research, 1989
This report describes the metabolism of apolipoprotein B-containing lipoproteins in seven familial hypercholesterolemic (FH) homozygotes and compares the results to the values obtained from five healthy control subjects.
R W James, B Martin, D Pometta, J C Fruchart, P Duriez, P Puchois, J P Farriaux, A Tacquet, T Demant, R J Clegg   +9 more
doaj   +1 more source